Growth Metrics

Merck (MRK) Cash & Current Investments (2009 - 2026)

Merck (MRK) reported Cash & Current Investments of $5.7 billion for Q1 2026, down 38.21% year-over-year from $9.2 billion in Q1 2025, and down 60.85% on a QoQ basis from $14.6 billion in Q4 2025.

Merck (MRK) has 18 years of Cash & Current Investments data on file, last reported at $5.7 billion in Q1 2026.

  • Quarterly Cash & Current Investments fell 38.21% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (down 38.21% YoY) and the FY2025 annual result came in at $14.6 billion, up 6.4% from the prior year.
  • Cash & Current Investments slipped to $5.7 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $18.2 billion in Q3 2025 and bottomed at $5.6 billion in Q1 2024.
  • The 5-year median for Cash & Current Investments is $10.1 billion (2022), against an average of $10.5 billion.
  • The widest annual swing landed in 2023, when Cash & Current Investments tumbled 46.23%; it then surged 92.99% in 2024.
  • Tracing MRK's Cash & Current Investments over 5 years: stood at $13.2 billion in 2022, then plunged by 46.23% to $7.1 billion in 2023, then jumped by 92.99% to $13.7 billion in 2024, then gained by 6.4% to $14.6 billion in 2025, then plunged by 60.85% to $5.7 billion in 2026.
  • Per Business Quant, the three latest MRK Cash & Current Investments figures stand at $5.7 billion (Q1 2026), $14.6 billion (Q4 2025), and $18.2 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 5.28 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 22.05 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 9.39 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 5.70 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 7.64 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 13.08 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 10.49 Bn
10 Gsk 88.34 Bn 83.66 Bn - 4.68 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.70 Bn
Dec 31, 2025 14.57 Bn
Sep 30, 2025 18.21 Bn
Jun 30, 2025 8.62 Bn
Mar 31, 2025 9.23 Bn
Dec 31, 2024 13.69 Bn
Sep 30, 2024 14.59 Bn
Jun 30, 2024 11.35 Bn
Mar 31, 2024 5.62 Bn
Dec 31, 2023 7.09 Bn
Sep 30, 2023 8.77 Bn
Jun 30, 2023 6.38 Bn
Mar 31, 2023 10.39 Bn
Dec 31, 2022 13.19 Bn
Sep 30, 2022 11.25 Bn
Jun 30, 2022 10.13 Bn
Mar 31, 2022 8.93 Bn
Dec 31, 2021 8.10 Bn
Sep 30, 2021 10.02 Bn
Jun 30, 2021 8.58 Bn
Mar 31, 2021 6.98 Bn
Dec 31, 2020 8.05 Bn
Sep 30, 2020 7.36 Bn
Jun 30, 2020 11.10 Bn
Mar 31, 2020 7.43 Bn
Dec 31, 2019 10.45 Bn
Sep 30, 2019 8.02 Bn
Jun 30, 2019 7.11 Bn
Mar 31, 2019 8.80 Bn
Dec 31, 2018 8.86 Bn
Sep 30, 2018 10.29 Bn
Jun 30, 2018 7.59 Bn
Mar 31, 2018 7.35 Bn
Dec 31, 2017 8.50 Bn
Sep 30, 2017 16.30 Bn
Jun 30, 2017 14.07 Bn
Mar 31, 2017 14.64 Bn
Dec 31, 2016 14.34 Bn
Sep 30, 2016 13.07 Bn
Jun 30, 2016 11.83 Bn
Mar 31, 2016 12.94 Bn
Dec 31, 2015 13.43 Bn
Sep 30, 2015 12.09 Bn
Jun 30, 2015 11.37 Bn
Mar 31, 2015 15.60 Bn
Dec 31, 2014 15.72 Bn
Sep 30, 2014 14.35 Bn
Jun 30, 2014 13.40 Bn
Mar 31, 2014 20.51 Bn
Dec 31, 2013 17.49 Bn
Sep 30, 2013 18.17 Bn
Jun 30, 2013 18.10 Bn
Mar 31, 2013 13.02 Bn
Dec 31, 2012 16.14 Bn
Sep 30, 2012 17.36 Bn
Jun 30, 2012 17.45 Bn
Mar 31, 2012 15.57 Bn
Dec 31, 2011 14.97 Bn
Sep 30, 2011 14.62 Bn
Jun 30, 2011 13.98 Bn
Mar 31, 2011 13.03 Bn
Dec 31, 2010 12.20 Bn
Sep 30, 2010 10.62 Bn
Jun 30, 2010 9.94 Bn
Mar 31, 2010 9.78 Bn
Dec 31, 2009 9.60 Bn
Sep 30, 2009 22.30 Bn
Jun 30, 2009 13.87 Bn
Mar 31, 2009 6.02 Bn